• Scenario-Driven Solutions with M344 for Reliable HDAC Assays

  2026-04-22

  This article delivers scenario-based, evidence-driven guidance for biomedical researchers seeking reproducible cell viability, proliferation, and cytotoxicity results using M344 (SKU A4105), a potent histone deacetylase inhibitor. Explore real-world Q&A on experimental design, protocol optimization, and vendor selection, with actionable insights and validated parameters for maximizing workflow reliability in cancer biology and HIV latency research.

• Enhancing Assay Reproducibility: Losmapimod (SKU B4620) in C

  2026-04-21

  This article examines real-world challenges in cell viability and inflammation assays, demonstrating how Losmapimod (SKU B4620) provides reproducible, data-driven solutions for p38 MAPK pathway studies. By integrating recent mechanistic insights and scenario-based Q&A, biomedical researchers can optimize experimental design, interpretation, and reagent selection with confidence.

• Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod

  2026-04-21

  This study introduces a patient-derived gastric cancer assembloid system that integrates matched tumor organoids and stromal subpopulations, offering a physiologically relevant platform for investigating tumor-stroma interactions and drug resistance. The model enhances the predictive power of preclinical testing and opens new avenues for personalized therapeutic strategies.

• Bifendate Disrupts Autophagy and Reduces Lipid Droplet Accum

  2026-04-20

  This study uncovers the mechanistic action of bifendate (DDB) in liver cells, demonstrating its capacity to inhibit autophagy at several stages and attenuate oleic acid-induced lipid droplet accumulation. These findings refine our understanding of DDB's hepatoprotective effects and provide a methodological basis for dissecting autophagy-lipid interactions in metabolic disease models.

• DAPT (GSI-IX) in Organogenesis: Precision Tools for Notch Pa

  2026-04-20

  Discover how DAPT (GSI-IX), a potent γ-secretase inhibitor, enables precise control of Notch signaling in advanced organoid and disease models. This article delivers deep protocol insights and practical decision-making guidance for Alzheimer's disease, cancer, and stem cell research.

• Ribociclib Succinate (LEE011): Deep Dive into CDK Inhibition

  2026-04-19

  Explore how Ribociclib succinate (LEE011 succinate), a potent CDK inhibitor, enables advanced cancer research—going beyond standard protocols to reveal assay-critical nuances, solubility dynamics, and translational insights. Discover unique guidance for optimizing cell proliferation and cell cycle regulation studies.

• Benzyl-activated Streptavidin Magnetic Beads: Applied Workfl

  2026-04-18

  Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) from APExBIO offer high-specificity capture of biotinylated molecules, outperforming conventional beads in protein, nucleic acid, and cell-based assay workflows. Their hydrophobic, BSA-blocked design streamlines immunoprecipitation, protein interaction studies, and drug screening, delivering reproducibility and low background in complex samples.

• Adefovir-Induced Hypophosphatemic Osteochondrosis Mimicking

  2026-04-17

  This study presents a rare case where long-term Adefovir therapy for chronic hepatitis B induced hypophosphatemic osteochondrosis with clinical and radiological features mimicking ankylosing spondylitis (AS). The findings highlight the importance of integrating clinical, laboratory, and medication history to avoid misdiagnosis in patients exhibiting spondyloarthropathy-like symptoms.

• Azilsartan Medoxomil in Hypertension: Meta-Analysis Insights

  2026-04-16

  A recent meta-analysis synthesizing data from 11 randomized controlled trials (RCTs) confirms that azilsartan medoxomil (TAK 491) provides superior blood pressure reduction compared to control therapies, including in populations with diabetes. The findings reinforce the agent's efficacy and safety, supporting its use in essential hypertension treatment research and informing the design of future cardiovascular studies.

• Phosphatase Inhibitor Cocktail 2: Decoding Signal Fidelity i

  2026-04-15

  Explore how Phosphatase Inhibitor Cocktail 2 preserves protein phosphorylation in advanced signaling studies. Discover unique assay guidance and insights from mitochondrial stress research for precision in phosphoprotein analysis.

• Afatinib (BIBW 2992): Optimizing Assays in Tumor-Stroma Rese

  2026-04-14

  Explore how Afatinib, an irreversible ErbB kinase inhibitor, advances precision in cancer biology research by enabling more accurate modeling of EGFR, HER2, and HER4 pathways within physiologically relevant tumor-stroma assembloid systems. Uncover unique protocol strategies and translational insights not found in existing Afatinib content.

• TCAIM-Mediated OGDH Degradation Regulates Mitochondrial Meta

  2026-04-13

  This study reveals that the mitochondrial DNAJC co-chaperone TCAIM selectively binds and reduces a-ketoglutarate dehydrogenase (OGDH) protein levels via HSPA9 and LONP1. This novel post-translational mechanism suppresses OGDH complex activity, profoundly altering mitochondrial metabolism and cellular carbohydrate catabolism.

• PA-824: Bicyclic Nitroimidazole Derivative for Tuberculosis

  2026-04-13

  PA-824 stands out as a dual-mechanism, high-purity bicyclic nitroimidazole derivative that enables robust, reproducible inhibition of both drug-sensitive and drug-resistant Mycobacterium tuberculosis. This guide details experimental workflows, comparative advantages, and troubleshooting strategies to maximize research impact with this APExBIO compound.

• Gefitinib (ZD1839): Optimizing EGFR Inhibition in Patient-De

  2026-04-12

  Explore how Gefitinib (ZD1839) enables precise EGFR signaling pathway inhibition in advanced assembloid cancer models. This article uniquely analyzes protocol decisions, stromal interactions, and practical assay design for next-generation cancer research.

• Machine Learning Uncovers Senolytics: Implications for EGFR/

  2026-04-12

  The referenced study demonstrates a machine learning pipeline for the discovery of novel senolytic compounds, validated across multiple senescence modalities in human cell lines. This computational approach cuts drug screening costs and has implications for targeted therapies, including those involving EGFR and ErbB2 inhibition in cancer research.

16043 records 1/1070 page Next 12345 下5页 Last page